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Abstract
 .An L1210 cell line showing a 300-fold resistance to the cytostatic effect of 9- 2-phosphonylmethoxyethyl adenine
 .  .PMEA designated L1210rPMEA-1 was selected in cell culture upon exposure of wild-type L1210r0 cells to
stepwise-increased drug concentrations. The mutant L1210rPMEA-1 cell line was characterized by an unusual specificity
in that the cytostatic activity was severely impaired only for PMEA and the closely related 2,6-diaminopurine derivative
 .  .PMEDAP, but not for its guanine counterpart PMEG or for 9- 3-hydroxy-2-phosphonylmethoxypropyl adenine HPMPA .
The L1210rPMEA-1 cell line showed poor resistance to the cytostatic activity of the lipophilic PMEA prodrug
 .bis POM PMEA and virtually kept its PMEA resistance profile in the presence of indomethacin, excluding resistance of the
cells to PMEA and PMEDAP by an increased efflux of the drugs. Intracellular purine nucleotide pool labelling studies with
adenine, hypoxanthine and glycine revealed that PMEArPMEDAP resistance did not originate from a defect in the
enzymatic pathways of purine nucleotides. ATP, AMP and cAMP, but not adenosine, adenine, HPMPA and inhibitors of
nucleoside transport carriers markedly interfered with PMEA uptake in L1210r0 cells. The L1210rPMEA-1 cells proved
to have less than 10% of the PMEA uptake capacity of wild-type L1210r0 cells as measured by rapid sampling kinetics as
w 3 xwell as long-term incubation experiments. After a 24-h incubation period, the intracellular levels of 2,8- H PMEA and its
phosphorylated metabolites were ;10-fold lower in L1210rPMEA-1 cells than in L1210r0 cells. Our observations point
to a compromised and highly specific PMEArPMEDAP uptake as the molecular basis for the pronounced PMEA resistance
of the mutant L1210rPMEA-1 cells. q 1998 Elsevier Science B.V.
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1. Introduction
 .Acyclic nucleoside phosphonates ANP represent
a class of compounds that exhibits a potent and
) Corresponding author. Fax: q32-16-33-73-40; E-mail:
jan.balzarini@rega.kuleuven.ac.be
selective activity against a wide variety of DNA
w xviruses andror retroviruses 1–5 . These compounds
contain a phosphate group linked to the acyclic alkyl
side chain of purine or pyrimidine bases through a
 .P–C phosphonate bond. The ANP derivatives are
taken up by the cells in an unaltered intact form. This
is mainly due to the peculiar characteristics of the
unnatural P–C bond, which is chemically very stable
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and resistant to phosphorolytic cleavage by cellular
esterases. Furthermore, 9- 2-phosphonylmetho-
.  .  .xyethyl adenine PMEA Fig. 1 , one of the proto-
types of the ANPs, is resistant to deamination i.e.,
.by adenosine deaminase and AMP-deaminase to its
hypoxanthine derivative, and also is not cleaved i.e.,
. w xby purine nucleoside phosphorylase to adenine 6 .
AMP kinase derived from L1210 cells has been
shown to convert PMEA to its mono- and diphospho-
 . w xrylated derivatives PMEAp and PMEApp 7,8 .
 .Also, 5-phosphoribosyl-1-pyrophosphate PRPP syn-
thetase from E. coli, rat liver and human erythrocyte
origin has been shown to recognize PMEA as a
 .Fig. 1. Structural formula of PMEA, PMEDAP, bis POM PMEA,
 .  .S -HPMPA and S -HPMPDAP.
w xsubstrate 6,8–10 . Only PMEAp and PMEApp are
detected as the major metabolites of PMEA in MT-4
w xand CEM cells 6,11 . Thus, metabolism of PMEA in
these cell lines is relatively simple and straightfor-
ward. However, the phosphonyl group makes PMEA
negatively charged at physiological pH, and hence
the cellular uptake and oral bioavailability of the
w xcompound are relatively poor 12,13 . This could be
overcome by the synthesis of its lipophilic bis piva-
. w  .loyloxymethyl ester derivative bis POM PMEA;
xadefovir dipivoxyl , which is currently under investi-
gation as an oral prodrug for PMEA, in phase IIrIII
clinical trials in AIDS patients.
The mechanism of cellular uptake of PMEA has
remained largely unknown. The two reports that have
appeared on the subject have indicated that uptake of
PMEA by human H9 and simian Vero cells does not
occur via the nucleoside transport system. Indeed, the
wclassical nucleoside transport inhibitors 6- 4-nitro-
.x  .benzyl mercaptopurine riboside NBMPR and
dipyridamole were found not to affect PMEA influx
in H9 and Vero cells under conditions where trans-
port of adenosine and thymidine was markedly inhib-
w xited 14,15 . The slow and temperature-dependent
kinetics further suggested an endocytosis-like mecha-
nism for the cellular uptake of the ANP derivatives
w x14,16 . Another preliminary study pointed to a trans-
port carrier-mediated process, based on findings that
were suggestive for an energy- and sodium-depen-
w xdent saturable PMEA influx in simian Vero cells 15 .
w xInterestingly, Cihlar et al. 17 have isolated a plasma
 .membrane protein 50 kDa from HeLa S3 cells that
may mediate the transport process of PMEA. Finally,
w xRobbins et al. 18 isolated a PMEA-resistant mutant
CEM cell line. The cell line had a lower mitochon-
drial AMP kinase activity, and evidence was pro-
vided that it was endowed with an enhanced efflux
mechanism for PMEA.
In this study we provided evidence that resistance
of L1210 cells to the cytostatic activity of PMEA
may likely be due to a compromised influx of these
drugs into the drug-exposed tumor cells. Most re-
markably, the pronounced resistance was limited to
PMEA and its closely related PMEDAP derivative
whilst the cells kept virtually the same sensitivity to
other acyclic nucleoside phosphonates including the
 .guanine derivative i.e., PMEG , and the hydrox-
 .ypropyl derivative i.e., HPMPA .
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2. Materials and methods
2.1. Cells
Murine leukaemia L1210 cells were obtained from
 .the American Type Culture Collection ATCC
 .Rockville, MD .
2.2. Compounds
 .PMEA and bis POM PMEA were provided by Dr.
 .N. Bischofberger Gilead Sciences, Foster City, CA .
The 2,6-diaminopurine and guanine counterparts of
PMEA designated PMEDAP and PMEG, respec-
.  . tively , S -9- 3-hydroxy-2-phosphonylmethoxypro-
. w . x  .  .pyl adenine S -HPMPA , S -HPMPDAP and S -
HPMPG were synthesized by Dr. A. Holy Czech´
.Academy of Sciences, Prague, Czech Republic . Ver-
apamil, genistein, cyclosporin A, indomethacin, AMP
 .and ATP were from Sigma St. Louis, MO .
2.3. Radiochemicals
w 3 x wThe radiolabelled precursors 8- H adenine, G-
3 x w 14 xH hypoxanthine and U- C glycine were obtained
from Amersham Belgium SArNV Brussels, Bel-
.gium . Their radiospecificities were 23, 3.4, and 0.104
w 3 x Cirmmol, respectively. 2,8- H PMEA 17
.  .Cirmmol and ribavirin 10 Cirmmol were from
 .Moravek Biochemicals Brea, CA .
2.4. Cytostatic assays
All assays were performed in 96-well microtiter
 .plates Falcon, Becton Dickinson, Grenoble, France .
To each well were added 5–7.5 =104 L1210,
L1210rPMEA-0.1 or L1210rPMEA-1 cells and a
given amount of the test compound. The cells were
allowed to proliferate for 48 h at 378C. Then, the
cells were counted in a Coulter counter Coulter
.Electronics, Harpenden, Herts, UK . The 50% in-
 .hibitory concentration IC was defined as the com-50
pound concentration required to reduce the number of
viable cells by 50%.
2.5. Selection of PMEA-resistant L1210 cells
A total of 20-ml cultures of wild-type L1210r0
cells at ;500 000 cellsrml were exposed to 50 mM
PMEA. The drug concentration was kept constant
 .during at least 5 cell passages 21 days before the
PMEA concentration was raised to 100 mM ;25
.mgrml . Then, the cells were kept at a fixed PMEA
concentration for up to ;12 further passages 51
. days , after which the resulting cell line designated
.L1210rPMEA-0.1 was obtained and frozen in liquid
nitrogen. Starting from the L1210rPMEA-0.1 cell
line, the PMEA concentration was progressively
 .raised to 1 mM ;250 mgrml via intermediate
PMEA concentrations of 150, 200, 400 and 500 mM.
The 1 mM PMEA concentration was reached after 44
 .days eight subcultivations , and kept constant for
 .another 25 days seven passages before the cell line
 .designated L1210rPMEA-1 was frozen in liquid
nitrogen. All experiments carried out with the
L1210rPMEA-0.1 and L1210rPMEA-1 cells were
performed after the cells were additionally cultured in
drug-free medium for at least 1 to 2 weeks.
[ 3 ] [ 3 ]2.6. Incorporation of 8- H adenine, G- H hypo-
[ 14 ]xanthine and U- C glycine into L1210r0 and
L1210rPMEA-1 purine nucleotide pools
w 3 x w 3 xThe incorporation of 8- H adenine, G- H hypo-
w 14 xxanthine and U- C glycine into purine nucleotide
pools was measured in 5 ml L1210r0 and
L1210rPMEA-1 cell cultures at ;600 000 cellsrml.
 .Radiolabelled precursors 5 mCircell culture were
added to the cell cultures for 6 h, after which time
period, cell extracts were prepared for HPLC analysis
as in Section 2.7.
[ 3 ]2.7. Metabolism of 2,8- H PMEA in murine
leukaemia L1210 cells
Murine leukaemia L1210r0 and L1210rPMEA-1
cells were seeded at 300 000 cellsrml in 5 ml tissue
 2.culture flasks 25 cm and incubated with 20 mCi
w 3 x  .2,8- H PMEA 0.45 mM for 24 h. Then, cells were
centrifuged at 48C, thoroughly washed three times
 .with ice-cold medium without serum and precipi-
 .tated with cold trichloroacetic acid 10% . After cen-
trifugation, the supernatants were neutralized with
tri-n-octyl-amine in Freon. HPLC analysis of neutral-
ized cell extracts was carried out using a Partisil-SAX
radial compression column. The chromatographic
separation of the metabolites was principally as de-
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w xscribed before 6 , and based on a gradient from 7
 .  .mM NH H PO , pH 3.8 to 0.25 M NH H PO4 2 4 4 2 4
q0.5 M KCl, pH 4.5.
[ 3 ]2.8. Uptake of 2,8- H PMEA into L1210r0 and
L1210rPMEA-1 cells
A total of 8-ml cell cultures containing 500 000
L1210r0 or L1210rPMEA-1 cellsrml were incu-
w 3 xbated at 378C for 1 h. Then, 2,8- H PMEA was
administered to the cell cultures at 1 mCirml and
unlabelled PMEA was added to obtain a final PMEA
concentration of 0.2, 2.0, 20, 200 or 2000 mM. In
w 3 xfact, 1 mCirml of undiluted 2,8- H PMEA repre-
sents 0.06 mM of PMEA, the amount of which could
be neglected by addition of unlabelled PMEA. At
different time points i.e., 0, 5, 10, 15, 20, 30, 60 and
.90 min , 1 ml of the cell suspension was immediately
cooled at 08C, centrifuged for 6 min at 1200 rpm and
subsequently washed trice with ice-cold medium.
Then, the cell precipitate was resuspended in 1 ml
water containing 1% Triton X-100, mixed and as-
sayed for radioactivity in 10 ml of the scintillation
 .cocktail High Save Wallac . In a second set of
w 3 xexperiments, uptake of 0.2 mM 2,8- H PMEA was
measured in wild-type L1210r0 cells after short
incubation periods of 0, 0.5, 1, 2, 3, 4 and 6.5 min,
using essentially the same technology as described
 .above. It was ascertained that i the washing proce-
dures were sufficient to result in a radioactivity back-
ground in the supernatants that was far below the
radioactivity associated with the PMEA-incubated
 .cells, ii within the short incubation periods, the
effect of intracellular metabolism of PMEA to its
mono- and diphosphorylated derivatives was negligi-
 .ble; and iii the cells were cooled at a sufficiently
w 3 xhigh speed, so that no 2,8- H PMEA taken up by the
cells could leak out into the medium PMEA uptake
.was abolished at 48C .
3. Results
3.1. Selection of murine leukaemia L1210 cell lines
resistant to the cytostatic acti˝ity of PMEA
Wild-type L1210r0 cells were cultivated in the
presence of increasing amounts of PMEA in the cell
culture medium. During this selection procedure two
L1210 cell lines were isolated that were able to grow
in the presence of 100 m M designated
. L1210rPMEA-0.1 and 1000 mM PMEA desig-
.nated L1210rPMEA-1 , respectively. As soon as the
highest PMEA concentrations were reached in the
 .cell cultures i.e., 100 and 1000 mM, respectively ,
both cell lines were further grown for an additional
five to 10 subcultivations in the presence of fixed
PMEA concentrations before the drug was removed
from the culture medium and the sensitivity of the
mutant cell lines to the cytostatic effects of various
nucleoside and ANP analogues were evaluated. Kary-
 .otyping genotyping of L 1210r 0 and
L1210rPMEA-1 cells revealed no fundamental dif-
 .ferences between both cell lines data not shown .
This indicates that it can be excluded that cross-con-
tamination occurred in the original L1210 or the
mutant L1210rPMEA-1 cell cultures with other cells
that had an intrinsic resistance to PMEA.
3.2. Sensiti˝ityrresistance spectrum of L1210r0,
L1210 r PMEA-0.1 and L1210 r PMEA-1 against
acyclic purine nucleoside phosphonates and purine
and pyrimidine antimetabolites
A series of ANP analogues that are structurally
closely related to PMEA were evaluated for their
cytostatic activity against wild-type L1210 cells and
the two PMEA-resistant L1210 cell lines derived
thereof.
PMEA proved ;10-fold and ;300-fold, respec-
tively, less cytostatic to L1210rPMEA-0.1 and
L1210rPMEA-1 cells than to wild-type L1210r0
 .cells Table 1 . The closely related 2,6-diaminopurine
derivative PMEDAP proved 14- and 135-fold, respec-
tively, less cytostatic to L1210rPMEA-0.1 and
L1210rPMEA-1 cells than to wild-type L1210r0
cells. In contrast, the guanine derivative PMEG was
only 6- to 7-fold less cytostatic to the mutant cell
 .lines than to the wild-type. Also S -HPMPA and
 .S -HPMPDAP, that differ from PMEA and
PMEDAP by an additional –CH OH group in the2
 .alkyl side chain Fig. 1 , did not show markedly
reduced cytostatic activity against the mutant cell
 .lines. Also, S -HPMPG was equally cytostatic to the
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Table 1
Inhibitory effects of test compounds on the proliferation of wild-type and PMEA-resistant L1210 cell lines
 .Compound IC mgrml50
L1210r0 L1210rPMEA-0.1 L1210rPMEA-1
 .  .PMEA 1.6 "0.23 17 "4.1 G500
 .  .  .PMEDAP 0.50 "0.20 7.1 "1.4 67 "24
 .  .  .PMEG 0.18 "0.01 1.2 "0.25 1.3 "0.31
 .  .  .  .S -HPMPA 20 "3.1 21 "6.7 44 "3.5
 .  .  .  .S -HPMPDAP 9.6 "1.1 21 "1.8 35 "7
 .  .  .  .S -HPMPG 40 "3.1 39 "3 40 "4
 .  .  .  .Bis POM PMEA 1.7 "0.60 1.7 "0.05 6.6 "0.93
 .  .  .cAMP 223 "2.3 227 "27 1160 "213
 .  .  .PAA 185 "10 190 "10 162 "12
 .  .  .PFA 202 "22 180 "5 190 "5
 .  .  .Tubercidin 0.088 "0.007 0.084 "0.009 0.069 "0.004
 .  .  .EICAR 0.173 "0.067 0.116 "0.016 0.15 "0.15
 .  .  .Ribavirin 12 "3.1 9.9 "0.1 45.5 "1
 .  .  .Hydroxyurea 4.3 "1 3.2 "1 9 "0.25
 .  .  .dThd 8.5 "2.7 9.3 "0.47 15 "3.5
 .  .  .5-BrdUrd 11 "1 11 "0.35 6.17 "0.6
 .  .  .Methothrexate 0.005 "0.001 0.005 "0.001 0.006 "0.0025
 .  .  .5-F-dUrd 0.003 "0.001 0.003 "0.0001 0.002 "0.01
 .  .  .5-F-Ura 0.25 "0.02 0.132 "0.044 0.136 "0.028
 .  .  .araC 0.008 "0.0007 0.010 "0 0.011 "0.0002
Guanine G500 )500 )500
Data represent the mean values for at least two to five independent experiments. Values between parentheses represent the standard
deviation values.
 .three cell lines evaluated Table 1 . Cyclic AMP
 .cAMP was 5-fold less inhibitory to L1210rPMEA-1
than to wild-type L1210r0 cell proliferation. Interest-
ingly, the L1210rPMEA-1 cells did not show a more
than 5-fold resistance to the bis-pivaloyloxymethyl
w  . xester derivative of PMEA bis POM PMEA . Phos-
 .phonoacetic acid PAA and phosphonoformic acid
 .PFA did not differ at all in their cytostatic activity
against wild-type L1210r0 and the mutant L1210
cell lines.
The following antimetabolites of purine and pyrim-
idine metabolism were also included in this study: the
adenosine kinase inhibitor tubercidin; the IMP dehy-
drogenase inhibitors EICAR and ribavirin; the ri-
bonucleotide reductase inhibitor hydroxyurea; the
thymidylate synthase inhibitor 5-fluoro-dUrd; the di-
hydrofolate reductase inhibitor methotrexate; and also
 .thymidine dThd , 5-bromo-dUrd, 5-fluorouracil,
 .guanine and cytosine arabinoside araC . None of
these compounds showed marked differences in their
cytostatic activity against the wild-type and the two
 .mutant L1210 cell lines Table 1 .
3.3. Effect of ˝erapamil, genistein, cyclosporin A,
indomethacin, AMP and ATP on the cytostatic acti˝-
ity of PMEA against L1210r0 and L1210rPMEA-1
cells
The drugs verapamil, genistein, cyclosporin A and
indomethacin had no marked effect on the cytostatic
activity of PMEA against wild-type L1210r0 cells
 .Table 2 . Also, when the PMEA-resistant cell line
was incubated in the presence of subtoxic concentra-
tions of verapamil, genistein or cyclosporin A to-
gether with high concentrations of PMEA, the
L1210rPMEA-1 cells kept full resistance to the ANP
 .analogue Table 2 . Indomethacin did not signifi-
cantly decrease the degree of resistance of
 . L1210rPMEA-1 cells to PMEA ;G2.5-fold Ta-
.ble 2 , whereas it markedly did so for a PMEA-re-
sistant human erythroleukemia K562 cell line ;40-
. w xfold 19 . The mechanism of PMEA resistance of the
latter cell line is likely to be due to an increased
efflux of PMEA from the drug-exposed cells our
.unpublished data . When 350, 70 and 14 mgrml of
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Table 2
Effect of verapamil, genistein, cyclosporin A, indomethacin and
AMP and ATP on the cytostatic activity of PMEA against
L1210r0 and L1210rPMEA-1 cells
a  .In combination with IC mgrml of PMEA50
L1210r0 L1210rPMEA-1
None 4.0 G500
 .Verapamil 20 mgrml 6.5 )250
 .Genistein 4 mgrml 6.0 )250
 .Cyclosporin A 4 mgrml 5.8 )250
 .Indomethacin 50 mM 2.4 258
b .AMP 350 mgrml y G500
 .70 mgrml 1.1 G500
 .14 mgrml 2.6 G500
b .ATP 500 mgrml y G500
 .100 mgrml 2.8 G500
 .20 mgrml 2.7 375
a50% inhibitory concentration, or PMEA concentration required
to inhibit tumor cell proliferation by 50%. The drugs were added
at subtoxic concentrations.
bAMP and ATP were toxic to L1210r0 cells at the highest
concentration tested.
AMP and 500, 100 and 20 mgrml ATP were evalu-
ated for their effect on the cytostatic activity of
PMEA against L1210r0 and L1210rPMEA-1 cells,
no marked decrease or increase of the IC value of50
PMEA was observed. The IC of PMEA against50
L1210r0 cells was 1.6 mgrml, compared with 2.1–
2.6 mgrml in the presence of 200 or 40 mM AMP
and 2.8 and 2.7 mgrml in the presence of ATP. The
IC of PMEA against L1210rPMEA-1 was 50050
mgrml, and proved 375 to 500 mgrml in the pres-
ence of AMP or ATP. It should be mentioned that
ATP and AMP were toxic to L1210r0 but not to
L1210rPMEA-1 cells when administered at their
highest concentration 350 mgrml for AMP and 500
.mgrml for ATP to the cell cultures.
3.4. Purine nucleotide metabolism in wild-type and
PMEA-resistant L1210 cell lines
The radiolabelling of the adenine and guanine
nucleotide pools were studied in wild-type L1210 and
mutant L1210rPMEA-1 cells, using the radiolabelled
wsalvage purine nucleotide synthesis precursors 8-
3 x w 3 xH adenine and G- H hypoxanthine, and the radiola-
belled de novo purine nucleotide synthesis precursor
w 14 xU- C glycine, that were added to L1210r0 and
L1210rPMEA-1 cell cultures during a 6 h-incubation
period.
The radiolabelling of the adenine and guanine
w 3 x w 3 xnucleotide pools by 8- H Ade and G- H Hx was
approximately 2- to 2.5-fold higher in the mutant
L1210rPMEA-1 cells compared to the wild-type
 .L1210r0 cells Table 3 . However, the wild-type and
mutant L1210 cell lines did not reveal marked differ-
ences in the ratio of radiolabelled adenine nucleotides
vs. guanine nucleotides when starting from either
w 3 x w 3 x8- H adenine or G- H hypoxanthine. Indeed, gua-
nine nucleotide pools were 10- to 15-fold less effi-
ciently radiolabelled than the adenine nucleotide pools
w 3 xif starting from 8- H adenine and 6- to 7-fold less
w 3 xefficiently radiolabelled if starting from G- H hypo-
xanthine. This difference should be ascribed to the
partial release of tritium at the C-2 position of hypox-
anthine during the conversion of IMP to xanthine
X  .nucleoside 5 -phosphate XMP via the IMP dehydro-
w xgenase reaction 14 . When radiolabelling of the ade-
nine and guanine nucleotide pools was compared in
both wild-type and mutant L1210 cell lines using the
wde novo purine nucleotide synthesis precursor U-
14 xC glycine, no qualitative or quantitative differences
 .were observed Table 3 . Under our experimental
conditions, the radiolabelling of the guanine nu-
w14 xcleotide pools by C glycine was only 2- to 2.5-fold
Table 3
Purine nucleotide metabolism in murine leukemia L1210 tumor cell lines sensitive and resistant to the cytostatic activity of PMEA
Cell line Radiolabelled precursors
3 3 14 3 3 14w x w x w x w x w x w x8- H Ade G- H Hx U- C Gly 8- H Ade G- H Hx U- C Gly
14 143 a 6 3 a 6w x  . w x  .H or C adenine nucleotides dpmr10 cells H or C guanine nucleotides dpmr10 cells
L1210r0 104 676 43 942 6454 6529 6963 2699
L1210rPMEA-1 180 814 101 527 6360 17 566 14 056 2877
aValues are the mean of at least two to three independent experiments.
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Table 4
w 3 xUptake and metabolism of 0.45 mM 2,8- H PMEA after a 24 h
incubation period in wild-type and mutant L1210rPMEA-1 cells
9Intracellular metabolite nmolr10 cells
L1210r0 L1210rPMEA-1
3w x2,8- H PMEA 1.2"0.36 0.101"0.023
3w x2,8- H PMEAp 0.071"0.012 0.006"0.002
3w x2,8- H PMEApp 0.051"0.027 0.011"0.005
Data represent the mean of two independent experiments.
less efficient than that of the adenine nucleotide
pools.
[ 3 ]3.5. Uptake and metabolism of 2,8- H PMEA in
L1210r0 and L1210rPMEA-1 cells
w 3 xUptake of 2,8- H PMEA and metabolism to the
 .monophosphate PMEAp and diphosphate PMEApp
derivative was studied in wild-type L1210r0 and the
PMEA-resistant L1210rPMEA-1 cells after the cells
w 3 xhad been exposed to 0.45 mM 2,8- H PMEA for 24
 .h Table 4 . As reported earlier for human MT-4 and
w xCEM cells 6,9 , no PMEA metabolites other than its
mono- and diphosphorylated derivative were de-
tected. The latter metabolites were present in the wild
type L1210 cells at 15 to 25 fold lower levels than
 .the parent compound PMEA Table 4 . In the
L1210rPMEA 1 cells 10 fold lower levels of PMEA
and its phosphorylated metabolites were detected than
in the wild type L1210r0 cells.
Since ribavirin is a nucleoside analogue that is
phosphorylated by adenosine kinase and further con-
verted to its 5X di and 5X triphosphate derivatives by
AMP kinase and NDP kinase, respectively, it would
be useful to investigate the metabolism of this com-
pound to reveal metabolic differences in the adeno-
sine “ ATP pathway in both L1210r0 and
L1210rPMEA 1 cell cultures. Therefore, we studied
w3 the uptake and metabolism of H ribavirin in both
wild type and mutant L1210 cell lines, but neither
qualitative nor quantitative differences in the intra-
cellular appearance of ribavirin and its phosphory-
 .lated metabolites were found data not shown . These
data argue against a significant metabolic defect in
the ATP synthesis pathway in the L1210rPMEA 1
cells, and are in agreement with our findings that
metabolism of adenine and guanine is not strikingly
different between mutant and wild type L1210 cell
lines.
[ 3 ]3.6. Influx studies of 2,8- H PMEA in L1210r0
and L1210rPMEA 1 cells
w 3 xThe influx of 2,8- H PMEA in L1210r0 and
L1210rPMEA 1 cells was studied over a time period
of up to 90 min with different concentrations of
PMEA. In the wild type L1210 cell line, equilibrium
levels of PMEA in the cells were reached within 15
 .min of exposure Fig. 2 . A total of 50% of this
PMEA was taken up by the cells within the first 5
min of exposure. At an extracellular concentration of
w0.2 mM PMEA, the following amounts of 2,8-
3 x 6H PMEA were measured in 10 L1210 cells: 17 400
 .  .dpm 19 pmole after 5 min, 29 200 dpm 32 pmole
 .after 10 min, and 32 800–35 600 dpm 36–39 pmole
 .the equilibrium level after 15 min. Higher initial
 .PMEA concentrations i.e., 2, 20 and 200 mM re-
sulted in a 3.2, 19.5 and 133-fold higher PMEA
influx, respectively. No marked saturation of PMEA
influx was observed upon incubation of L1210r0
cells with 2 mM PMEA. When PMEA transport was
 .  .Fig. 2. PMEA influx in L1210r0 v and L1210rPMEA-1 ‘
cells in function of incubation time. Data are mean of six to nine
independent experiments. Initial PMEA concentration was 0.2
mM. Insert represents linear PMEA influx at short incubation
 .time points. Data are the mean of two independent experiments.
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measured during short-time incubations i.e., 0.5, 1,
.2, 3, 4 and 6.5 min , PMEA influx proved to be
 .linear in time insert of Fig. 2 . In the mutant
L1210rPMEA-1 cells equilibrium of PMEA influx
was only reached after 30 min. Equilibrium drug
influx levels at an initial concentration of 0.2 mM
PMEA were reached at 2600–3200 dpm 2.9–3.5
. 6pmole PMEAr10 cells, that is at an intracellular
PMEA level that is ;12-fold lower than that ob-
tained for the wild-type L1210r0 cells. At 10-fold
and 100-fold higher initial PMEA concentrations i.e.,
.2 and 20 mM , influx levels of PMEA were 15- and
60-fold higher, respectively, in the L1210rPMEA-1
 .cells data not shown . Also, 50% of the PMEA
equilibrium level was obtained after 10 min, which is
2-fold longer than the time required for wild-type
L1210r0 cells.
Influx of 0.2 mM PMEA in wild-type L1210r0
cells could be markedly prevented in the presence of
 . exogenously added AMP 0.2 mM and ATP 0.2
. mM percentage of inhibition: 88 and 92%, respec-
.  .tively , but not in the presence of adenosine 2 mM
 .or adenine 2 mM . At concentrations that were
100-fold higher than the PMEA concentration, adeno-
sine and adenine started to affect PMEA influx.
 .However, 2 mM and 20 mM S -HPMPA did not
w 3 xmarkedly affect influx of 0.2 mM 2,8- H PMEA
 . into the L1210 cells data not shown ; cAMP 0.2
. w 3 xmM inhibited 2,8- H PMEA influx by 36%.
4. Discussion
PMEA influx in murine leukaemia L1210 cells
occurs at a considerably lower rate than the nucleo-
side carrier facilitated transport of natural nucleosides
such as thymidine and adenosine. However, PMEA
influx appears to occur at least ;60-fold more effi-
ciently in murine L1210 cells than in human lympho-
cyte CEM and H9 cells, and ;20-fold more effi-
wciently than in murine carcinoma FM3A cells Ref.
w x x 14 , and data not shown . The markedly higher 5- to
.10-fold cytostatic activity of PMEA against L1210
cells than CEM, Moltr4 and Raji cells likely results
from the much higher PMEA uptake and hence,
.metabolism by L1210 cells than by the human T-
and B-lymphoblastoid cells. In fact, a strong correla-
tion is noticed between PMEA uptake and eventual
 .cytostatic activity data not shown . It is somewhat
puzzling that a 10-fold decreased uptake of PMEA by
the L1210rPMEA-1 cells leads to a 300-fold resis-
tance to the cytostatic activity of the drug. The
PMEA-resistant cells have been selected during a
step-wise process in which seven escalating PMEA
concentrations were exposed to the cell cultures over
a period of at least 4 months. Therefore, it cannot be
excluded that other events that may have happened
during the selection process, further contribute to the
resistance. For example, if higher endogenous dATP
pools in the L1210rPMEA-1 cells may exist, it
would lower the efficacy of PMEA to inhibit cellular
DNA polymerases. In fact, our findings on the more
pronounced purine salvage reflected by a higher con-
version of radiolabelled adenine and hypoxanthine in
the adenine nucleotide pools of L1210rPMEA-1 cells
cannot exclude that the eventual intracellular dATP
levels are also increased, and thus, may lower the
inhibitory activity of the drug on L1210rPMEA-1
cell proliferation. It should also be mentioned that a
decreased presence of a toxic intracellular metabolite
does not obligatorily result in an exactly similarly
decreased cytostatic activity, since the inhibition ki-
 .netics of the enzyme s responsible for the eventual
cytostatic activity need not necessarily to be linear.
It has been reported that PMEA influx into cells is
w xtemperature-dependent 14,15 . These observations
are consistent with an active, carrier-mediated trans-
port of PMEA in L1210 cells. By selecting a PMEA-
resistant L1210 cell line that has a more than 10-fold
reduction in PMEA influx, as compared to the wild-
type cells, we provided evidence for the existence of
a specific transport carrier for PMEA in L1210 cells.
Such a transport-deficient cell line has not been
previously reported for any of the acyclic nucleoside
phosphonates, and seems to be unique in the sense
that the cytostatic activity of only PMEA and its
closely related 2,6-diaminopurine derivative
PMEDAP, but not of the guanine derivative PMEG
 .  .or S -HPMPA and S -HPMPDAP is altered. Be-
sides PMEA and PMEDAP, the nucleotide carrier
may also show a high specificity toward the adenine
nucleotides AMP and ATP but not to adenosine or
adenine, since only the adenine nucleotides were able
to efficiently compete with PMEA uptake by the
L1210 cells.
 .Our findings that bis POM PMEA is almost
equally cytostatic to the wild-type L1210r0 and mu-
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tant L1210rPMEA-1 cells argue against the possibil-
ity that the PMEA-resistant L1210 cell line that we
selected in cell culture displays an enhanced PMEA
efflux mechanism. Indeed, due to its highly lipophilic
 .character, bis POM PMEA is taken up by the cells
through passive diffusion and then releases PMEA
 .inside the cells after cleavage of bis POM PMEA by
w xcellular esterases 20–22 . If cellular resistance to the
cytostatic activity of PMEA would have resulted
from an increased efflux of PMEA from the mutant
cell line, one may have expected a marked resistance
of the L1210rPMEA-1 cell line to the cytostatic
 .activity of bis POM PMEA as well, and this was
clearly not the case. Thus, our L1210rPMEA-1 mu-
tant cell line differs from the PMEA-resistant K562
w xcells isolated in our laboratory 19 and from the
PMEA-resistant CEM cells isolated by Robbins et al.
w x18 . The mutant CEM cells were markedly resistant
 . to PMEA, PMEDAP and bis POM PMEA 123- to
. w x 533-fold 18 , and partially resistant to PMEG 30-
. w x  . w xfold 18 and HPMPA 12-fold 18 , and were shown
to have an enhanced excretion of PMEA in the
w xmedium 18 . Also, we could not detect a marked
difference between L1210r0 and L1210rPMEA-1
cells in their capacity to release radiolabelled AMP or
ATP in the extracellular environment upon incuba-
w 3 x  .tion with 8- H adenine data not shown . No differ-
ences were shown for the de novo metabolic path-
 .ways of purine nucleotide glycine metabolism in
L1210r0 and L1210rPMEA-1 cells. Although rela-
.tively minor differences in the salvage metabolism
of the natural purine bases adenine and hypoxan-
.thine were observed between L1210r0 and
L1210rPMEA-1 cells, it is highly unlikely that they
 .may solely account for the pronounced resistance of
PMEA to L1210rPMEA-1 cells. Thus, our
metabolism data revealed that metabolic differences
in purine nucleotide metabolism do most likely not
account for the pronounced PMEA resistance in the
L1210rPMEA-1 cells. To exclude efflux mecha-
nisms involved in PMEA resistance of the L1210
mutant cell lines, we investigated the effects of vera-
pamil, genistein, cyclosporin A and indomethacin on
the drug-resistant cell line. Verapamil and cy-
closporin A are able to reverse multidrug resistance
 . MDR phenotype by down-regulation of Pgp a 170-
.kDa membrane glycoprotein, involved in MDR
w x23,24 . The isoflavinoid genistein is a modulator of
the multidrug resistance-associated protein MRP a
180–195 kDa membrane protein, not related to the
. w xPgp MDR 25,26 . Also, indomethacin is a well-
known blocker of anion channels and interferes with
w xanion transport 27 . However, none of the drugs
were able to markedly alter the resistance of
 .L1210rPMEA-1 to PMEA Table 2 . Thus, our ex-
perimental data point to a specific transport carrier-
mediated influx of PMEA in L1210 cells, that is
functionally distinct from those carrier systems that
mediate nucleoside and nucleobase transport into the
cells. This is also evident from the lack of inhibition
of PMEA influx by NBMPR nitrobenzylmercap-
.topurine riboside and dipyridamole and the lack of
competition of adenine and adenosine for PMEA
uptake. Our observations are in agreement with the
w xobservations of Cihlar et al. 17 , who isolated a
plasma membrane carrier protein from HeLa S3 cells
that specifically recognized PMEDAP and PMEA.
They also found that natural nucleotides, but not
nucleosides and nucleobases interfered with PMEA
uptake in the HeLa S3 cells. Thus, the PMEA-re-
sistant L1210 cell line selected by us may have a
defect in a membrane protein similar to that isolated
w xfrom HeLa cells by Cihlar et al. 17 . This possibility
is now subject of further investigation. The mem-
brane proteins of the L1210r0 and L1210rPMEA-1
cell lines responsible for PMEA transport should now
be isolated according to the procedures described by
w x Cihlar et al. 17 i.e., vectorial labelling of plasma
membrane proteins with Na125I combined with affin-
.ity chromatography . This will allow us to further
characterize the molecular properties of the PMEA
carrier and help us to reveal its natural function.
Thus, PMEA and the closely related PMEDAP on the
one hand, and the mutant PMEArPMEDAP-resistant
L1210 cell lines on the other hand may represent
useful tools to further investigate, identify and char-
acterize this highly specific purine nucleotide trans-
port carrier present on the membrane of murine L1210
 .and possibly other cells.
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